Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)

TreatResp is a double-blind, individually randomized, multi-centre adaptive platform trial. TreatResp aims to establish an adaptive platform trial aimed at evaluating the clinical- and cost-effectiveness, practical challenges, and outcomes of therapeutics for respiratory pathogens in non-hospitalized patients. Participants will be randomized to receive usual care (i.e., supportive care and symptom relief) or a study therapeutic, which will be determined by the TreatResp Therapeutics Committee. The primary outcomes being evaluated is time to recovery.

NCT Number	NCT07314905
Lead Sponsor	Unity Health Toronto Collaborators: Canadian Institutes of Health Research (CIHR), Health Canada
Conditions	Influenza A, Influenza B, SAR-CoV-2, Acute Respiratory Infections (ARIs)
Enrollment	264 participants
Start Date	2026-01-02
Primary Completion	2027-03-31 (estimated)
Study Completion	2027-04-24 (estimated)
Updated on ClinicalTrials.gov	2026-01-02